4d Molecular Therapeutics Inc (FDMT) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket
 


4d Molecular Therapeutics Inc   (NASDAQ: FDMT)


4d Molecular Therapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is 4d Molecular Therapeutics Inc's ROI in the second quarter of 2026?
4d Molecular Therapeutics Inc recorded a cumulative net loss of $-179 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -39.29%.

Within the Healthcare sector 413 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3463 to 3551.

Definition and Formula of Return on Investment



Return On Investment (Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM -10.3 % -17.19 % -20.8 % -12.5 % 8.25 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 445 470 523 387 439
Return On Investment (TTM) -39.29 % -35.4 % -30.5 % -45.33 % -38.58 %
FDMT's Overall Ranking # 3551 # 3463 # 2839 # 0 # 2922
Seq. Investment Change TTM 0.33 % -1.05 % -0.46 % -9.23 % -7.37 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -179 -161 -140 -209 -196




Return On Investment FDMT's Ranking
Within: No.
Industry # 53
Sector # 414
Overall # 3551

Return On Investment Statistics
High Average Low
-22.85 %
-32.41 %
-43.65 %
(Jun 30 2024)   (Sep 30 2025)







Financial Statements
4d Molecular Therapeutics Inc's II. Quarter Investments $ 445 Millions FDMT's Balance sheet
4d Molecular Therapeutics Inc's II. Quarter Income $ -73 Millions Quarterly FDMT's Income Statement
FDMT's Income by Division See FDMT's Income by Division


FDMT Annual Return On Investment (Dec 31 2025)
2025
(Dec 31 2024)
2024
(Dec 31 2023)
2023
(Dec 31 2022)
2022
(Dec 31 2021)
2021
Total Investments in Millions 523 531 321 246 337
Y / Y Investment Growth -1.6 % 65.52 % 30.4 % -27 % 24.14 %
Net Income in Millions -140 -161 -101 -107 -71
Y / Y Net Income Growth - - - - -
Annual Return On Investment -26.8 % -30.28 % -31.42 % -43.68 % -21.15 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
FDMT's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for FDMT's Competitors
Subscribers only: Roi for 4d Molecular Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for FDMT's Customers

Other Ratios
FDMT's Roa FDMT's Inventory Turnover Ratio FDMT's Growth Rates FDMT's Dividend Statistics
FDMT's Profitability Ratios FDMT's Asset Turnover Ratio FDMT's Dividend Growth
FDMT's Roe FDMT's Valuation Ratios FDMT's Financial Strength Ratios FDMT's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI


Date modified: 2026-09-26T07:39:01+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.